hit counter
Aeglea BioTherapeutics, Inc. (AGLE) Stock News Sentiment & Price - Sentifly
AGLE - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Aeglea BioTherapeutics, Inc. (AGLE)

USA
Biotechnology
NASDAQ
AGLE Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AGLE Latest news
PRNewsWire
Neutral
Aeglea BioTherapeutics to Participate in Multiple Conferences in September 2021
2021-09-01 08:30

AUSTIN, Texas, Sept. 1, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced its participation in the following medical and investor conferences:  Investor Meetings 2021 Wells Fargo Virtual Healthcare Conference, September 9 H.C.

Zacks Investment Research
Positive
Aeglea Biotherapeutics (AGLE) Reports Q2 Loss, Tops Revenue Estimates
2021-08-05 11:25

Aeglea (AGLE) delivered earnings and revenue surprises of 47.37% and 112.34%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire
Neutral
Aeglea BioTherapeutics Reports Second Quarter 2021 Financial Results and Corporate Highlights
2021-08-05 08:30

AUSTIN, Texas, Aug. 5, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced financial results for the second quarter ended June 30, 2021, and reviewed recent corporate updates and program highlights. "2021 is proving to be a pivotal year for Aeglea.

PRNewsWire
Neutral
Aeglea BioTherapeutics Appoints Jim Kastenmayer as General Counsel
2021-07-15 08:30

AUSTIN, Texas, July 15, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Jim Kastenmayer, Ph.D., J.D., as general counsel.

PRNewsWire
Neutral
Aeglea BioTherapeutics Announces Publication of 20 Week Data from Phase 1/2 and Open-Label Extension Studies of Pegzilarginase for the Treatment of Arginase 1 Deficiency in the Journal of Inherited Metabolic Disease
2021-07-14 16:30

AUSTIN, Texas, July 14, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the publication of 20 week data from the Phase 1/2 clinical trial of pegzilarginase for the treatment of Arginase 1 Deficiency (ARG1-D), a rare, progressive and devastating disease characterized by high levels of the amino acid arginine. Pegzilarginase is a novel, recombinant human arginase 1 enzyme designed to lower levels of arginine that is also being investigated in PEACE, an ongoing Phase 3 pivotal trial for the treatment of ARG1-D.

PRNewsWire
Neutral
Aeglea BioTherapeutics Appoints Jonathan D. Alspaugh as Chief Financial Officer
2021-07-08 08:30

AUSTIN, Texas, July 8, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the appointment of Jonathan D. Alspaugh as Chief Financial Officer.

PRNewsWire
Neutral
Aeglea BioTherapeutics Doses First Patient in a Phase 1/2 Clinical Trial of AGLE-177, a Potential First-in-Class Treatment for Homocystinuria
2021-06-24 08:30

AUSTIN, Texas, June 24, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced the dosing of the first patient in the Company's first-in-human Phase 1/2 clinical trial investigating AGLE-177 for the treatment of Homocystinuria. The markedly elevated plasma homocysteine levels lead to a wide range of life-altering complications and reduced life expectancy in people with Homocystinuria.

Seeking Alpha
Positive
Aeglea BioTherapeutics: Late-Stage Enzyme Therapeutic Biotech Approaches Promising Phase 3 Data Announcement
2021-05-19 11:04

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company developing enzyme therapeutics for rare metabolic diseases with limited treatment options. Aeglea's pipeline consists of two clinical-stage therapeutics and one in the late-pre-clinical stage covering primarily metabolic enzyme-related indications including arginase 1 deficiency, the indication of its lead Phase 3 therapeutic, Pegzilarginase.

PRNewsWire
Neutral
Aeglea BioTherapeutics Reports First Quarter 2021 Financial Results and Corporate Highlights
2021-05-10 08:30

AUSTIN, Texas, May 10, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today reported its first quarter 2021 financial results, and provided recent corporate and program highlights. "We've had a strong start to 2021 and I am excited to see the significant momentum we have built for our pegzilarginase program from a clinical perspective as well as strengthening our commercial foundation in preparation for a potential FDA approval and launch.

PRNewsWire
Neutral
Aeglea BioTherapeutics Launches THINK ARGININE™, a Disease Education Initiative to Improve Awareness and Diagnosis of Arginase 1 Deficiency
2021-05-06 08:30

AUSTIN, Texas, May 6, 2021 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced the launch of THINK ARGININE, a disease education initiative focused on improving the awareness and diagnosis of Arginase 1 Deficiency (ARG1–D), a devastating and progressive rare metabolic disease. People living with ARG1-D are faced with debilitating, progressive disease manifestations that create significant challenges in daily life, including mobility issues, intellectual disability, developmental delays and seizures.

Loading more news...